



## Clinical trial results:

### Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq

#### Summary

EudraCT number	2015-005297-37
Trial protocol	GB
Global end of trial date	14 February 2020

#### Results information

Result version number	v1 (current)
This version publication date	13 December 2021
First version publication date	13 December 2021
Summary attachment (see zip file)	Clinical Study report (BESTT Clinical Study Report_v3.0_22.11.2021.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	3552
-----------------------	------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	King's College Hospital NHS Foundation Trust
Sponsor organisation address	Denmark Hill, London, United Kingdom, SE5 9RS
Public contact	Dr Frank Post, King's College Hospital NHS Foundation Trust, 0044 20784857795776, frank.post@kcl.ac.uk
Scientific contact	Dr Frank Post, King's College Hospital NHS Foundation Trust, 0044 20784857795776, frank.post@kcl.ac.uk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 October 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	14 February 2020
Global end of trial reached?	Yes
Global end of trial date	14 February 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to compare the changes in bone mineral density (BMD) over 96 weeks in women who switch from Truvada/NNRTI to Triumeq, as compared to women who stay on their current Truvada/NNRTI regimen.

Protection of trial subjects:

Patients are free to withdraw consent for study treatment and/or consent to participate in the study at any time and without the prejudice to further treatment. Patients who withdraw from study treatment, but are willing to continue to participate in the follow-up visits, should be followed according to the procedures outlined in the protocol.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 May 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 91
Worldwide total number of subjects	91
EEA total number of subjects	91

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	87
From 65 to 84 years	4
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

HIV positive women  $\geq 40$  years on stable antiretroviral therapy consisting of TDF/ FTC (or 3TC) plus an NNRTI with HIV RNA  $< 50$  copies/mL for at least 12 months will be eligible to enter the trial.

### Pre-assignment period milestones

Number of subjects started	102 <sup>[1]</sup>
Number of subjects completed	91

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	screen fail: 11
----------------------------	-----------------

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The pre-assignment period includes participants who were screened and then not enrolled into the study

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Switch ABC/3TC/DTG
------------------	--------------------

Arm description:

Switch to Triumeq (abacavir 600 mg, lamivudine 300 mg, dolutegravir 50 mg), one tablet daily

Arm type	Experimental
Investigational medicinal product name	Triumeq
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: 600mg abacavir, 300mg lamivudine, 50mg dolutegravir

Daily dose: 1 tablet

Duration of use: 96 weeks

<b>Arm title</b>	Ongoing TDF/FTC/NNRTI
------------------	-----------------------

Arm description:

Participants who are randomised to arm 2 will continue on their current antiretroviral therapy. This will contain tenofovir disoproxil fumarate, emtricitabine or lamivudine, and an NNRTI (nevirapine, efavirenz, etravirine, rilpivirine), administered singularly or as a fixed dose combination. Fixed dose combinations include Atripla, Eviplera or Truvada plus an NNRTI.

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: 245mg tenofovir disoproxil fumarate

Daily dose: 1 tablet once daily

Duration of use: 96 weeks

Investigational medicinal product name	Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: 150mg lamivudine or 300mg lamivudine

Daily dose: 300mg daily

Duration of use: 96 weeks

Investigational medicinal product name	Truvada
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: 245mg tenofovir disoproxil fumarate, 200mg emtricitabine

Daily dose: 1 tablet

Duration of use: 96 weeks

Investigational medicinal product name	Atripla
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: Efavirenz 600mg, emtricitabine 200mg, tenofovir disoproxil fumarate 245mg

Daily dose: 1 tablet

Duration of use: 96 weeks

Investigational medicinal product name	Eviplera
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: Rilpivirine 25mg, emtricitabine 200mg, tenofovir disoproxil fumarate 245mg

Daily dose: 1 tablet

Duration of use: 96 weeks

Investigational medicinal product name	Efavirenz
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: Efavirenz 600mg tablet or 200mg capsule  
Daily dose: 600mg  
Duration of use: 96 weeks

Investigational medicinal product name	Nevirapine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: Nevirapine 400mg prolonged release (PR) or 200mg tablet  
Daily dose: 400mg  
Duration of use: 96 weeks

Investigational medicinal product name	Etravirine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: 200mg  
Daily dose: Etravirine 400mg  
Duration of use: 96 weeks

Investigational medicinal product name	Rilpivirine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Unit strength: Rilpivirine 25mg  
Daily dose: 25mg  
Duration of use: 96 weeks

<b>Number of subjects in period 1</b>	Switch ABC/3TC/DTG	Ongoing TDF/FTC/NNRTI
Started	59	32
Completed	59	32

## Baseline characteristics

### Reporting groups

Reporting group title	Switch ABC/3TC/DTG
Reporting group description:	
Switch to Triumeq (abacavir 600 mg, lamivudine 300 mg, dolutegravir 50 mg), one tablet daily	
Reporting group title	Ongoing TDF/FTC/NNRTI
Reporting group description:	
Participants who are randomised to arm 2 will continue on their current antiretroviral therapy. This will contain tenofovir disoproxil fumarate, emtricitabine or lamivudine, and an NNRTI (nevirapine, efavirenz, etravirine, rilpivirine), administered singularly or as a fixed dose combination. Fixed dose combinations include Atripla, Eviplera or Truvada plus an NNRTI.	

Reporting group values	Switch ABC/3TC/DTG	Ongoing TDF/FTC/NNRTI	Total
Number of subjects	59	32	91
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
arithmetic mean	50.9	49.5	
standard deviation	± 7.0	± 6.0	-
Gender categorical			
Units: Subjects			
Female	59	32	91
Male	0	0	0

## End points

### End points reporting groups

Reporting group title	Switch ABC/3TC/DTG
Reporting group description: Switch to Triumeq (abacavir 600 mg, lamivudine 300 mg, dolutegravir 50 mg), one tablet daily	
Reporting group title	Ongoing TDF/FTC/NNRTI
Reporting group description: Participants who are randomised to arm 2 will continue on their current antiretroviral therapy. This will contain tenofovir disoproxil fumarate, emtricitabine or lamivudine, and an NNRTI (nevirapine, efavirenz, etravirine, rilpivirine), administered singularly or as a fixed dose combination. Fixed dose combinations include Atripla, Eviplera or Truvada plus an NNRTI.	

### Primary: • Between study-arm changes from baseline in total hip bone mineral density (BMD) at week 48

End point title	• Between study-arm changes from baseline in total hip bone mineral density (BMD) at week 48
End point description:	
End point type	Primary
End point timeframe: baseline to week 96	

End point values	Switch ABC/3TC/DTG	Ongoing TDF/FTC/NNRT I		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	59	32		
Units: g/cm <sup>2</sup>				
median (full range (min-max))				
Baseline	0.96 (0.92 to 0.99)	1.03 (0.98 to 1.08)		
Week 96	0.96 (0.93 to 1.00)	1.02 (0.98 to 1.07)		

### Statistical analyses

Statistical analysis title	Adjusted mean difference between study arms
Statistical analysis description: Intention to treat analyses.	
Comparison groups	Switch ABC/3TC/DTG v Ongoing TDF/FTC/NNRTI

Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	= 0.438
Method	Regression, Linear

Notes:

[1] - Intention to treat



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

baseline to week 96

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23
--------------------	----

### Reporting groups

Reporting group title	Switch ABC/3TC/DTG
-----------------------	--------------------

Reporting group description:

Switch to Triumeq (abacavir 600 mg, lamivudine 300 mg, dolutegravir 50 mg), one tablet daily

Reporting group title	Ongoing TDF/FTC/NNRTI
-----------------------	-----------------------

Reporting group description:

Participants who are randomised to arm 2 will continue on their current antiretroviral therapy. This will contain tenofovir disoproxil fumarate, emtricitabine or lamivudine, and an NNRTI (nevirapine, efavirenz, etravirine, rilpivirine), administered singularly or as a fixed dose combination. Fixed dose combinations include Atripla, Eviplera or Truvada plus an NNRTI.

Serious adverse events	Switch ABC/3TC/DTG	Ongoing TDF/FTC/NNRTI	
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 59 (15.25%)	2 / 32 (6.25%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Hysterectomy			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
perianal abscess			

subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Attempted suicide			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insomnia			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
papillary carcinoma			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroidectomy			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Mixed connective tissue disease			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Cellulitis			

subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	Switch ABC/3TC/DTG	Ongoing TDF/FTC/NNRTI	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	52 / 59 (88.14%)	25 / 32 (78.13%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	
General disorders and administration site conditions			
Hypothyroidism			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Abnormal dreams			
subjects affected / exposed	3 / 59 (5.08%)	0 / 32 (0.00%)	
occurrences (all)	3	0	
Insomnia			
subjects affected / exposed	3 / 59 (5.08%)	0 / 32 (0.00%)	
occurrences (all)	4	0	
Parasomnia			
subjects affected / exposed	4 / 59 (6.78%)	0 / 32 (0.00%)	
occurrences (all)	4	0	
Immune system disorders			
allergic reaction			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	2	
Anaemia			

subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
folic acid deficiency			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
hayfever			
subjects affected / exposed	3 / 59 (5.08%)	0 / 32 (0.00%)	
occurrences (all)	3	0	
low b12 and folate			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Vitamin D deficiency			
subjects affected / exposed	4 / 59 (6.78%)	1 / 32 (3.13%)	
occurrences (all)	5	1	
Reproductive system and breast disorders			
Adnexal mass			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
bulky uterus			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Dysmenorrhoea			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Endometrial thickening			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
fibroids			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
menorrhagia			
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	
Postmenopausal bleeding			

subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
vaginal bleeding			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
vaginal candidasis			
subjects affected / exposed	1 / 59 (1.69%)	1 / 32 (3.13%)	
occurrences (all)	1	1	
Respiratory, thoracic and mediastinal disorders			
chest infection			
subjects affected / exposed	3 / 59 (5.08%)	2 / 32 (6.25%)	
occurrences (all)	3	2	
cold/coryzal symptoms			
subjects affected / exposed	5 / 59 (8.47%)	6 / 32 (18.75%)	
occurrences (all)	5	6	
Cough			
subjects affected / exposed	9 / 59 (15.25%)	2 / 32 (6.25%)	
occurrences (all)	10	2	
post nasal drip			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Throat irritation			
subjects affected / exposed	3 / 59 (5.08%)	1 / 32 (3.13%)	
occurrences (all)	3	1	
Sinusitis			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Rhinorrhoea			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	
Depression			

subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	2 / 32 (6.25%) 2	
suicidal thoughts subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 32 (0.00%) 0	
low mood subjects affected / exposed occurrences (all)	4 / 59 (6.78%) 4	3 / 32 (9.38%) 3	
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	5 / 59 (8.47%) 5	3 / 32 (9.38%) 3	
Fatigue subjects affected / exposed occurrences (all)	5 / 59 (8.47%) 5	2 / 32 (6.25%) 2	
Headache subjects affected / exposed occurrences (all)	4 / 59 (6.78%) 4	2 / 32 (6.25%) 2	
Migraine subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	1 / 32 (3.13%) 1	
neurocognitive symptoms subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	1 / 32 (3.13%) 1	
Memory impairment subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 32 (0.00%) 0	
Eye disorders			
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	1 / 32 (3.13%) 1	
Blepharitis subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	1 / 32 (3.13%) 1	
itchy eyes			

subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
bilateral red eyelids			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Dry eye			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
sty			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Toothache			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Tooth infection			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
root canal			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Tooth abscess			
subjects affected / exposed	1 / 59 (1.69%)	1 / 32 (3.13%)	
occurrences (all)	1	1	
Tooth erosion			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
abdominal heat			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Abdominal pain			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Constipation			
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	

Diarrhoea			
subjects affected / exposed	5 / 59 (8.47%)	2 / 32 (6.25%)	
occurrences (all)	6	3	
Dyspepsia			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Flatulence			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Gastroenteritis			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Nausea			
subjects affected / exposed	1 / 59 (1.69%)	14 / 32 (43.75%)	
occurrences (all)	1	1	
reflux			
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	
stomach pain			
subjects affected / exposed	3 / 59 (5.08%)	0 / 32 (0.00%)	
occurrences (all)	3	0	
Vomiting			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Abscess			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
localised rash			
subjects affected / exposed	4 / 59 (6.78%)	1 / 32 (3.13%)	
occurrences (all)	4	1	
athletes foot			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
coldsore			



subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
darkened patches		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
Eczema		
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)
occurrences (all)	2	0
Skin infection		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	2	0
Swollen finger		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	2	0
Fungal skin infection		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
haemorrhoids		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
Hot flush		
subjects affected / exposed	1 / 59 (1.69%)	1 / 32 (3.13%)
occurrences (all)	1	1
infected hair follicle		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
Wound infection		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	2	0
itchiness		
subjects affected / exposed	4 / 59 (6.78%)	0 / 32 (0.00%)
occurrences (all)	4	0
Lichen planus		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
Lipodystrophy		

subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
shoulder lump			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Dry skin			
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	
Skin lesion			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
solar keratosis			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Proteinuria			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Kidney infection			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Urinary tract infection			
subjects affected / exposed	2 / 59 (3.39%)	2 / 32 (6.25%)	
occurrences (all)	2	2	
Micturition difficulty			
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	
Musculoskeletal and connective tissue disorders			
Weight increased			
subjects affected / exposed	3 / 59 (5.08%)	0 / 32 (0.00%)	
occurrences (all)	4	0	
body pain			

subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
painful ankles		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
arm pain		
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)
occurrences (all)	2	0
Back pain		
subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)
occurrences (all)	2	0
lower back muscle spasm		
subjects affected / exposed	0 / 59 (0.00%)	15 / 32 (46.88%)
occurrences (all)	0	1
body aches		
subjects affected / exposed	1 / 59 (1.69%)	1 / 32 (3.13%)
occurrences (all)	1	1
early changes of degeneration in spine		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
golfer's elbow		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
hip pain		
subjects affected / exposed	1 / 59 (1.69%)	1 / 32 (3.13%)
occurrences (all)	1	1
insertional tendinopathy		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
intermittent bilateral bony elbow pain		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
jaw pain		

subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
joint pain		
subjects affected / exposed	1 / 59 (1.69%)	2 / 32 (6.25%)
occurrences (all)	1	2
knee/ankle pain		
subjects affected / exposed	2 / 59 (3.39%)	1 / 32 (3.13%)
occurrences (all)	2	1
leg pain		
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	1
medial epicondylitis		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
Musculoskeletal pain		
subjects affected / exposed	2 / 59 (3.39%)	1 / 32 (3.13%)
occurrences (all)	2	1
neck strain		
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	1
Rheumatoid arthritis/osteoarthritis		
subjects affected / exposed	1 / 59 (1.69%)	1 / 32 (3.13%)
occurrences (all)	1	1
right glotal tendonitis		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
medial foot pain		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
Sciatic nerve pain		
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)
occurrences (all)	1	0
shoulder pain		
subjects affected / exposed	5 / 59 (8.47%)	1 / 32 (3.13%)
occurrences (all)	5	1
finger stiffness		

subjects affected / exposed	2 / 59 (3.39%)	0 / 32 (0.00%)	
occurrences (all)	2	0	
thigh pain			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
tingling in arms and legs			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
weak joints			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
ankle oedema			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
burn			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
banged knee			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
enlarged heart			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
left leg weakness			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
finger cut			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
left foot injury			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
face pain			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	
Infections and infestations			

ear pain			
subjects affected / exposed	2 / 59 (3.39%)	1 / 32 (3.13%)	
occurrences (all)	2	1	
fever			
subjects affected / exposed	1 / 59 (1.69%)	0 / 32 (0.00%)	
occurrences (all)	1	0	
Influenza			
subjects affected / exposed	5 / 59 (8.47%)	0 / 32 (0.00%)	
occurrences (all)	5	0	
respiratory infection			
subjects affected / exposed	3 / 59 (5.08%)	0 / 32 (0.00%)	
occurrences (all)	3	0	
Metabolism and nutrition disorders			
Anorexia nervosa			
subjects affected / exposed	0 / 59 (0.00%)	1 / 32 (3.13%)	
occurrences (all)	0	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/32985122>